# Natural Killer (NK) Cell Therapy in Locally Advanced HCC

> **NCT05040438** · PHASE2 · COMPLETED · sponsor: **Vaxcell Bio, Co., Ltd.** · enrollment: 17 (actual)

## Conditions studied

- Locally Advanced Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Vax-NK/HCC

## Key facts

- **NCT ID:** NCT05040438
- **Lead sponsor:** Vaxcell Bio, Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-15
- **Primary completion:** 2023-09-14
- **Final completion:** 2023-09-14
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040438, "Natural Killer (NK) Cell Therapy in Locally Advanced HCC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05040438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*